AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

Astrazeneca (AZN) closed the latest trading day at $70.25, indicating a +0.95% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.47%. Meanwhile, the Dow ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

AstraZeneca (NASDAQ:AZN), a global pharmaceutical firm, has announced a C$820 million (US$570 million) investment in Canada, ...

Investment analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of AstraZeneca in a note issued to ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms ...

(RTTNews) - The U.S. Food and Drug Administration approved AstraZeneca (AZN ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...